Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaidZymeworks to retain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results